RU2014144945A - Бис-полимерные липид-пептидные конъюгаты и наночастицы из них - Google Patents
Бис-полимерные липид-пептидные конъюгаты и наночастицы из них Download PDFInfo
- Publication number
- RU2014144945A RU2014144945A RU2014144945A RU2014144945A RU2014144945A RU 2014144945 A RU2014144945 A RU 2014144945A RU 2014144945 A RU2014144945 A RU 2014144945A RU 2014144945 A RU2014144945 A RU 2014144945A RU 2014144945 A RU2014144945 A RU 2014144945A
- Authority
- RU
- Russia
- Prior art keywords
- polymer
- conjugate
- peptide
- molecular weight
- group
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims 19
- 239000002105 nanoparticle Substances 0.000 title 1
- 239000000863 peptide conjugate Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000002245 particle Substances 0.000 claims 11
- 150000002632 lipids Chemical group 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000001165 hydrophobic group Chemical group 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000003473 lipid group Chemical group 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 239000005062 Polybutadiene Substances 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229920001477 hydrophilic polymer Polymers 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 229920002857 polybutadiene Polymers 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261622330P | 2012-04-10 | 2012-04-10 | |
| US61/622,330 | 2012-04-10 | ||
| US201261668923P | 2012-07-06 | 2012-07-06 | |
| US61/668,923 | 2012-07-06 | ||
| PCT/US2013/035924 WO2013155152A1 (en) | 2012-04-10 | 2013-04-10 | Bis-polymer lipid-peptide conjugates and nanoparticles thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014144945A true RU2014144945A (ru) | 2016-05-27 |
Family
ID=49328119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014144945A RU2014144945A (ru) | 2012-04-10 | 2013-04-10 | Бис-полимерные липид-пептидные конъюгаты и наночастицы из них |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2841083B1 (enExample) |
| JP (2) | JP6426600B2 (enExample) |
| KR (1) | KR20140143838A (enExample) |
| CN (1) | CN104379158A (enExample) |
| AU (1) | AU2013245989B2 (enExample) |
| CA (1) | CA2869984C (enExample) |
| IL (1) | IL235167A0 (enExample) |
| IN (1) | IN2014DN08781A (enExample) |
| MX (1) | MX2014012271A (enExample) |
| RU (1) | RU2014144945A (enExample) |
| WO (1) | WO2013155152A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9949927B2 (en) | 2012-04-10 | 2018-04-24 | The Regents Of The University Of California | Bis-polymer lipid-peptide conjugates and nanoparticles thereof |
| RU2732612C2 (ru) * | 2015-02-23 | 2020-09-21 | Ниппон Каяку Кабусики Каися | Блок-сополимерный конъюгат физиологически активного вещества |
| WO2017059338A1 (en) * | 2015-10-02 | 2017-04-06 | Cornell University | Enzyme-responsive peptide nanofiber compositions and uses thereof |
| CN112823000A (zh) * | 2018-10-12 | 2021-05-18 | 联邦高等教育系统匹兹堡大学 | 用于试剂递送的小聚合物载体 |
| CN119497732A (zh) * | 2023-06-19 | 2025-02-21 | 华南理工大学 | 基于序列固定聚赖氨酸的pH敏感膜裂解材料及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2329259C (en) | 1998-05-27 | 2003-08-05 | Avigen, Inc. | Convection-enhanced delivery of aav vectors |
| WO2003022250A2 (en) * | 2001-09-10 | 2003-03-20 | Celator Technologies Inc. | Unilamellar vesicles stabilized with short chain hydrophilic polymers |
| WO2009059450A1 (en) * | 2007-11-05 | 2009-05-14 | Shanghai Jiaotong University | Peptide ligand directed drug delivery |
| CA2724408A1 (en) * | 2008-05-19 | 2009-11-26 | The University Of North Carolina At Chapel Hill | Methods and compositions comprising novel cationic lipids |
| EP2414278B1 (en) * | 2009-04-03 | 2019-11-27 | University Of Houston | Metal nanoparticles functionalized with rationally designed coatings |
| PT2508170E (pt) * | 2009-12-03 | 2015-10-16 | Shanghai Hengrui Pharm Co Ltd | Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação |
| ES2659409T3 (es) | 2010-03-12 | 2018-03-15 | The Regents Of The University Of California | Conjugados de lípido-péptido-polímero y nanopartículas de los mismos |
-
2013
- 2013-04-10 WO PCT/US2013/035924 patent/WO2013155152A1/en not_active Ceased
- 2013-04-10 EP EP13776184.7A patent/EP2841083B1/en not_active Not-in-force
- 2013-04-10 AU AU2013245989A patent/AU2013245989B2/en not_active Ceased
- 2013-04-10 RU RU2014144945A patent/RU2014144945A/ru not_active Application Discontinuation
- 2013-04-10 KR KR1020147031418A patent/KR20140143838A/ko not_active Withdrawn
- 2013-04-10 JP JP2015505867A patent/JP6426600B2/ja not_active Expired - Fee Related
- 2013-04-10 IN IN8781DEN2014 patent/IN2014DN08781A/en unknown
- 2013-04-10 MX MX2014012271A patent/MX2014012271A/es unknown
- 2013-04-10 CA CA2869984A patent/CA2869984C/en active Active
- 2013-04-10 CN CN201380029919.7A patent/CN104379158A/zh active Pending
-
2014
- 2014-10-19 IL IL235167A patent/IL235167A0/en unknown
-
2018
- 2018-05-01 JP JP2018088026A patent/JP2018150327A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015520126A (ja) | 2015-07-16 |
| CA2869984C (en) | 2021-08-17 |
| MX2014012271A (es) | 2015-05-11 |
| JP6426600B2 (ja) | 2018-11-21 |
| CN104379158A (zh) | 2015-02-25 |
| AU2013245989B2 (en) | 2017-03-30 |
| EP2841083A1 (en) | 2015-03-04 |
| WO2013155152A1 (en) | 2013-10-17 |
| JP2018150327A (ja) | 2018-09-27 |
| AU2013245989A1 (en) | 2014-10-30 |
| EP2841083B1 (en) | 2020-08-05 |
| EP2841083A4 (en) | 2016-07-13 |
| IN2014DN08781A (enExample) | 2015-05-22 |
| KR20140143838A (ko) | 2014-12-17 |
| IL235167A0 (en) | 2014-12-31 |
| CA2869984A1 (en) | 2013-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Brain penetrating peptides and peptide–drug conjugates to overcome the blood–brain barrier and target CNS diseases | |
| Ruan et al. | Rethinking CRITID procedure of brain targeting drug delivery: circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internalization, and drug release | |
| Hao et al. | Membrane internalization mechanisms and design strategies of arginine-rich cell-penetrating peptides | |
| Fu et al. | RGD peptide-based non-viral gene delivery vectors targeting integrin αvβ3 for cancer therapy | |
| Wang et al. | Nanodisk-based glioma-targeted drug delivery enabled by a stable glycopeptide | |
| Pangburn et al. | Peptide-and aptamer-functionalized nanovectors for targeted delivery of therapeutics | |
| JP7756185B2 (ja) | ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法 | |
| Khalil et al. | High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression | |
| Georgieva et al. | Peptide-mediated blood-brain barrier transport of polymersomes | |
| Shi et al. | A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma | |
| ES2687987T3 (es) | Péptidos que penetran en las células para la administración intracelular de moléculas | |
| Seleci et al. | Smart multifunctional nanoparticles in nanomedicine | |
| CN107708671B (zh) | 包含钴卟啉-磷脂缀合物和聚组氨酸标签的纳米结构 | |
| Santos et al. | Peptide dendrimers: Drug/gene delivery and other approaches | |
| WO2014053879A1 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
| JP2012512175A5 (enExample) | ||
| Prencipe et al. | Forward precision medicine: Micelles for active targeting driven by peptides | |
| Mizrahy et al. | Targeting central nervous system pathologies with nanomedicines | |
| WO2011005098A1 (en) | Peptide ligands for targeting to the blood-brain barrier | |
| Jabbari | Targeted delivery with peptidomimetic conjugated self-assembled nanoparticles | |
| CN106924731A (zh) | 一种基于光动力疗法和化学疗法的联合肿瘤靶向治疗系统 | |
| Kumar et al. | PEGylation and cell-penetrating peptides: Glimpse into the past and prospects in the future | |
| Jankowski et al. | Cell-penetrating peptides as facilitators of cargo-specific nanocarrier-based drug delivery | |
| Perez-Martinez et al. | Dendrimers as vectors for genetic material delivery to the nervous system | |
| Wang et al. | Research progress on cyclic-peptide functionalized nanoparticles for tumor-penetrating delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20160411 |